Utrophin modulators to treat Duchenne muscular dystrophy (DMD): Phase 1b Clinical Trial Results of SMT C1100 (P2.006)
Jon Tinsley(Summit (United Kingdom)), Kay E. Davies(University of Oxford), Stefan Spinty(Alder Hey Children's NHS Foundation Trust), Imelda Hughes(Manchester University NHS Foundation Trust), David Roblin(The Francis Crick Institute), Helen Roper(Heart of England NHS Foundation Trust), Gary Layton(University of Geneva), A. Bracchi(Summit (United Kingdom)), Bina Tejura(Summit (United Kingdom)), Francesco Muntoni(Great Ormond Street Hospital), Valeria Ricotti(Solidus Biosciences (United States))
Cited by 1
Related Papers
Missense Mutations in the Rod Domain of the Lamin A/C Gene as Causes of Dilated Cardiomyopathy and Conduction-System Disease
|New England Journal of Medicine|1999|1.4k
Function and Genetics of Dystrophin and Dystrophin-Related Proteins in Muscle
|Physiological Reviews|2002|1.2k
A gene (PEX) with homologies to endopeptidases is mutated in patients with X–linked hypophosphatemic rickets
|Nature Genetics|1995|1.1k